Scholarlink

<p>Idiopathic sudden sensorineural hearing loss (iSSNHL) and acute acoustic trauma (AT) are commonly treated with corticosteroids, although evidence for optimal treatment strategies remains limited. Pioglitazone, a peroxisome proliferator–activated receptor-γ agonist with anti-inflammatory and anti-apoptotic properties, has been proposed as a potential adjunctive therapy. In this prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial conducted across five countries, 128 adults with severe to profound unilateral iSSNHL or AT were treated within 96&#xa0;h of symptom onset. Patients received standard corticosteroid therapy combined with intratympanic and/or oral pioglitazone or placebo. Hearing outcomes were assessed using changes in pure-tone audiometry at the most affected frequencies over 12&#xa0;weeks. All treatment groups showed significant hearing improvement over time; however, no additional benefit of pioglitazone was observed compared with placebo. Overall hearing thresholds improved substantially, while variations in corticosteroid dose and treatment duration did not influence recovery. These findings indicate that pioglitazone does not enhance hearing recovery when added to corticosteroid therapy, and that higher or prolonged corticosteroid dosing offers no measurable advantage. Further randomized controlled studies are warranted to better define effective treatment strategies for these conditions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pioglitazone does not improve standard steroid therapy for severe to profound sudden sensorineural hearing loss

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Nicole Peter,
  • Viktor Börlin,
  • Nick Sommerhalder,
  • Patrick Neff,
  • Alexander Bausch,
  • Claudia Berger,
  • Tobias Kleinjung

摘要

Idiopathic sudden sensorineural hearing loss (iSSNHL) and acute acoustic trauma (AT) are commonly treated with corticosteroids, although evidence for optimal treatment strategies remains limited. Pioglitazone, a peroxisome proliferator–activated receptor-γ agonist with anti-inflammatory and anti-apoptotic properties, has been proposed as a potential adjunctive therapy. In this prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial conducted across five countries, 128 adults with severe to profound unilateral iSSNHL or AT were treated within 96 h of symptom onset. Patients received standard corticosteroid therapy combined with intratympanic and/or oral pioglitazone or placebo. Hearing outcomes were assessed using changes in pure-tone audiometry at the most affected frequencies over 12 weeks. All treatment groups showed significant hearing improvement over time; however, no additional benefit of pioglitazone was observed compared with placebo. Overall hearing thresholds improved substantially, while variations in corticosteroid dose and treatment duration did not influence recovery. These findings indicate that pioglitazone does not enhance hearing recovery when added to corticosteroid therapy, and that higher or prolonged corticosteroid dosing offers no measurable advantage. Further randomized controlled studies are warranted to better define effective treatment strategies for these conditions.